Search Results

The LCx Neisseria gonorrhoeae Assay uses LCR™ (Ligase Chain Reaction) amplification technology in the LCx Probe System for the direct, qualitative detection of a specific target nucleic acid sequence in the Opa gene of Neisseria gonorrhoeae in female endocervical and male urethral swab specimens or in male and female ur ne specimens from symptomatic and asymptomatic males and females.

Device Description

AI/ML Overview

Here's an analysis of the provided text, outlining the acceptance criteria and study details for the LCx® Neisseria gonorrhoeae Assay:

Acceptance Criteria and Reported Device Performance

The acceptance criteria for this device are implicitly tied to demonstrating substantial equivalence to the culture method for Neisseria gonorrhoeae detection. The performance metrics presented (Sensitivity and Specificity) serve as the criteria by which this equivalence is assessed. While explicit sensitivity and specificity targets are not stated as "acceptance criteria" in the document, the presented ranges with 95% Confidence Intervals imply that the performance observed met the internal/regulatory expectations for substantial equivalence.

Table of Acceptance Criteria and Reported Device Performance (Based on provided data)

Metric	Sample Type	Symptomatology	Acceptance Criteria (Implicit)	Reported Performance (Fresh Specimens)	Reported Performance (Frozen Specimens)
Sensitivity	Female Endocervical	Asymptomatic	High	100.0% (69.2-100.0)	88.9% (70.8-97.6)
	Female Endocervical	Symptomatic	High	100.0% (83.2-100.0)	100.0% (92.5-100.0)
	Female Urine	Asymptomatic	High	100.0% (66.4-100.0)	92.0% (74.0-99.0)
	Female Urine	Symptomatic	High	85.0% (62.1-96.8)	95.6% (84.5-99.5)
	Male Urethra	Asymptomatic	High	100.0% (2.5-100.0)	85.7% (42.1-99.6)
	Male Urethra	Symptomatic	High	100.0% (92.5-100.0)	98.7% (95.5-99.2)
	Male Urine	Asymptomatic	High	100.0% (2.5-100.0)	85.7% (42.1-99.6)
	Male Urine	Symptomatic	High	97.9% (88.9-99.9)	99.4% (96.8-100.0)
	Total	Asymptomatic	High	100.0%	89.4%
	Total	Symptomatic	High	97.0%	98.8%
Specificity	Female Endocervical	Asymptomatic	High	95.6% (87.6-99.1)	98.2% (96.7-99.1)
	Female Endocervical	Symptomatic	High	99.1% (95.1-100.0)	97.2% (94.5-98.8)
	Female Urine	Asymptomatic	High	98.5% (91.7-100.0)	99.1% (95.3-100.0)
	Female Urine	Symptomatic	High	99.1% (95.0-100.0)	100.0% (98.1-100.0)
	Male Urethra	Asymptomatic	High	100.0% (95.1-100.0)	98.8% (95.7-99.9)
	Male Urethra	Symptomatic	High	97.8% (88.2-99.9)	97.6% (94.9-99.1)
	Male Urine	Asymptomatic	High	100.0% (95.1-100.0)	99.6% (97.5-100.0)
	Male Urine	Symptomatic	High	97.8% (86.2-99.9)	96.6% (93.5-98.4)
	Total	Asymptomatic	High	98.6%	98.6%
	Total	Symptomatic	High	98.7%	97.7%

Study Information:

Sample Size Used for the Test Set and Data Provenance:
- Fresh Specimens:
  - Asymptomatic Total: 300
  - Symptomatic Total: 446
  - Overall Fresh Total: 746
- Frozen Specimens:
  - Asymptomatic Total: 1169
  - Symptomatic Total: 1447
  - Overall Frozen Total: 2616
- Data Provenance: The study was conducted in four U.S. sites. The data is prospective, as it compares the LCx assay results to culture results from specimens collected in real-world clinical settings.
Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications:
- The document does not explicitly state the number of experts used or their qualifications for establishing the ground truth (culture results). However, it is a standard assumption in such studies that clinical microbiology laboratories, staffed by qualified microbiologists and technicians, performed the culture method and interpreted its results.
Adjudication Method for the Test Set:
- The document does not specify an adjudication method beyond "comparing assay results to results of culture." For discordant results (LCx positive, culture negative; or LCx negative, culture positive), it is common practice to perform further testing (e.g., re-culture, additional molecular tests, or follow-up clinical data) to resolve the discrepancy, but this is not mentioned.
Multi Reader Multi Case (MRMC) Comparative Effectiveness Study:
- No, an MRMC comparative effectiveness study was not performed as described in this summary. This study compares a new diagnostic device (LCx) to a comparator diagnostic method (culture), not the performance of human readers with and without AI assistance.
Standalone Performance Study (Algorithm Only Without Human-in-the-Loop):
- Yes, this study represents a standalone performance study of the LCx Neisseria gonorrhoeae Assay. The reported sensitivity and specificity values are for the device (algorithm) itself compared to the ground truth (culture), without human interpretation of the LCx results directly impacting the reported performance metrics. The results of the LCx are quantitative or qualitative outputs that are then interpreted.
Type of Ground Truth Used:
- The ground truth used was culture for Neisseria gonorrhoeae. This is a direct method for detecting the viable organism, making it a widely accepted "gold standard" for N. gonorrhoeae diagnosis.
Sample Size for the Training Set:
- The document does not mention a separate training set or its sample size for the LCx assay. This device likely relies on established molecular biology principles and was developed and optimized in laboratory settings, possibly using internal validation data not detailed here. For a diagnostic assay like this, the "training" would be more akin to assay development and optimization rather than machine learning model training on a distinct dataset.
How the Ground Truth for the Training Set Was Established:
- As no explicit training set is mentioned in the context of a machine learning model, the concept of establishing ground truth for a training set in that sense is not applicable here. The assay development would have involved using well-characterized Neisseria gonorrhoeae strains and other microorganisms, likely with their identities confirmed by established microbiological methods (e.g., culture, biochemical tests, sequencing) to ensure the assay's ability to detect the target and avoid cross-reactivity.

Ask a Question

Ask a specific question about this device

Page 1 of 1